Validation of the Italian Version of the Abbreviated Expanded Prostate Cancer Index Composite (EPIC-26) in Men with Prostate Cancer

Overview

Journal Health Qual Life Outcomes

Publisher Biomed Central

Specialty Public Health

Date 2019 Aug 30

PMID 31464649

Citations 9

Authors

Chiara Marzorati

Dario Monzani

Ketti Mazzocco

Marianna Masiero

Francesca Pavan

Massimo Monturano

Gabriella Pravettoni

Affiliations

Soon will be listed here.

Abstract

Background: This study aims to validate and evaluate the psychometric properties and reliability of the Italian version of the Expanded Prostate Cancer Index Composite - Short Form (EPIC-26), a measure of quality of life (QoL) for prostate cancer patients.

Methods: Two hundred and eighty-four prostate cancer patients completed the Italian version of the EPIC-26 questionnaire at 45 days (T1) and 3 months (T2) after robot-assisted radical prostatectomy (RARP). Psychometric properties were evaluated using structural equation modeling: the goodness of fit of the correlated five-factor model (CFFM) for the EPIC-26 was assessed using the confirmatory factor analysis (CFA), while longitudinal invariance was conducted to assess the ability of the EPIC-26 to measure QoL construct over time. Test-retest reliability was assessed as well by considering intraclass correlations.

Results: At T1, the CFFM model displayed a good fit to data. Similarly, the model showed an adequate fit also at T2. Results of the reliability analysis attested the acceptable internal consistency and test-retest reliability of each dimension: all Cronbach's alphas could be classified as acceptable (i.e., above .65) except for low Cronbach's alpha for hormonal dysfunction at T1 (i.e., .638) and urinary irritation at both waves. (i.e., respectively .585 and .518). Finally, psychometric properties were invariant over time and each of the five dimensions of QoL displayed from moderate (all ICCs above .500) to good test-retest reliability (i.e. ICC for urinary incontinence = .764).

Conclusions: Results of the CFA and the measurement invariance analysis demonstrated the validity of the Italian version of the EPIC-26 to assess QoL in prostate cancer patients. Its reliability and good psychometric qualities are well-supported, thus providing a valid tool to assess health-related quality of life and its change over time in prostate cancer patients.

Citing Articles

Development and validation of a questionnaire to measure the congenital heart disease of children's family stressor.

Zhang Y, Zhou H, Bai Y, Chen Z, Wang Y, Hu Q Front Public Health. 2024; 12:1365089.

PMID: 38751578 PMC: 11094312. DOI: 10.3389/fpubh.2024.1365089.

Psychometric validation of the Spanish version of the Expanded Prostate Cancer Index Composite-26.

Zamora V, Garin O, Suarez J, Jove J, Castells M, Ferrer F World J Urol. 2023; 41(12):3511-3518.

PMID: 37947846 PMC: 10693511. DOI: 10.1007/s00345-023-04691-7.

Urologic latency time during uroflow stop test with electromyography: an incontinence detector in rehabilitation after robotic radical prostatectomy.

Boni A, Gervasoni F, LoMauro A, Del Zingaro M, Maiolino G, Galletti C Eur J Phys Rehabil Med. 2022; 59(1):94-102.

PMID: 36305651 PMC: 10035442. DOI: 10.23736/S1973-9087.22.07365-8.

Creation and validation of the harmonized Arabic version of the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP).

Awad M, Hallgarth L, Barayan G, Shahait M, Abu-Hijlih R, Farkouh A Arab J Urol. 2022; 20(2):88-93.

PMID: 35530568 PMC: 9067989. DOI: 10.1080/2090598X.2021.2002636.

A novel mHealth App (RyPros) for prostate cancer management: an accessibility and acceptability study.

Wang G, Wu B, Chen J, Yu G, Lin D, Wang G Transl Androl Urol. 2021; 10(10):3723-3736.

PMID: 34804816 PMC: 8575583. DOI: 10.21037/tau-21-459.

References

Wei J, Dunn R, Litwin M, Sandler H, Sanda M . Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000; 56(6):899-905. DOI: 10.1016/s0090-4295(00)00858-x. View

Beaton D, Bombardier C, Guillemin F, Ferraz M . Guidelines for the process of cross-cultural adaptation of self-report measures. Spine (Phila Pa 1976). 2000; 25(24):3186-91. DOI: 10.1097/00007632-200012150-00014. View

Miller D, Sanda M, Dunn R, Montie J, Pimentel H, Sandler H . Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol. 2005; 23(12):2772-80. DOI: 10.1200/JCO.2005.07.116. View

Takegami M, Suzukamo Y, Sanda M, Kamoto T, Namiki S, Arai Y . [The Japanese translation and cultural adaptation of Expanded Prostate Cancer Index Composite (EPIC)]. Nihon Hinyokika Gakkai Zasshi. 2005; 96(7):657-69. DOI: 10.5980/jpnjurol1989.96.657. View

Hsiao C, Loescher L, Moore I . Symptoms and symptom distress in localized prostate cancer. Cancer Nurs. 2007; 30(6):E19-32. DOI: 10.1097/01.NCC.0000300163.13639.bc. View

Shrout P, Fleiss J . Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979; 86(2):420-8. DOI: 10.1037//0033-2909.86.2.420. View

Szymanski K, Wei J, Dunn R, Sanda M . Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology. 2010; 76(5):1245-50. PMC: 3152317. DOI: 10.1016/j.urology.2010.01.027. View

Chung K, Kim J, Lim S, Kim T, Han D, Lee S . Development and validation of the korean version of expanded prostate cancer index composite: questionnaire assessing health-related quality of life after prostate cancer treatment. Korean J Urol. 2010; 51(9):601-12. PMC: 2941808. DOI: 10.4111/kju.2010.51.9.601. View

De Sousa A, Sonavane S, Mehta J . Psychological aspects of prostate cancer: a clinical review. Prostate Cancer Prostatic Dis. 2012; 15(2):120-7. DOI: 10.1038/pcan.2011.66. View

10.

Alves E, Medina R, Andreoni C . Validation of the Brazilian version of the Expanded Prostate Cancer Index Composite (EPIC) for patients submitted to radical prostatectomy. Int Braz J Urol. 2013; 39(3):344-52. DOI: 10.1590/S1677-5538.IBJU.2013.03.07. View

11.

Schmidt S, Garin O, Pardo Y, Valderas J, Alonso J, Rebollo P . Assessing quality of life in patients with prostate cancer: a systematic and standardized comparison of available instruments. Qual Life Res. 2014; 23(8):2169-81. PMC: 4155169. DOI: 10.1007/s11136-014-0678-8. View

12.

Beyer B, Huland H, Feick G, Graefen M . ["Expanded prostate cancer index composite" (EPIC-26): Results of functional treatment in patients with localized prostate cancer]. Urologe A. 2015; 54(11):1591-5. DOI: 10.1007/s00120-015-3922-0. View

13.

Zelefsky M, Poon B, Eastham J, Vickers A, Pei X, Scardino P . Longitudinal assessment of quality of life after surgery, conformal brachytherapy, and intensity-modulated radiation therapy for prostate cancer. Radiother Oncol. 2016; 118(1):85-91. PMC: 4848377. DOI: 10.1016/j.radonc.2015.11.035. View

14.

Fossa S, Storas A, Steinsvik E, Myklebust T, Eri L, Loge J . Psychometric testing of the Norwegian version of the Expanded Prostate Cancer Index Composite 26-item version (EPIC-26). Scand J Urol. 2016; 50(4):280-5. DOI: 10.3109/21681805.2016.1163617. View

15.

Miller K, Siegel R, Lin C, Mariotto A, Kramer J, Rowland J . Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016; 66(4):271-89. DOI: 10.3322/caac.21349. View

16.

Koo T, Li M . A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research. J Chiropr Med. 2016; 15(2):155-63. PMC: 4913118. DOI: 10.1016/j.jcm.2016.02.012. View

17.

Donovan J, Hamdy F, Lane J, Mason M, Metcalfe C, Walsh E . Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med. 2016; 375(15):1425-1437. PMC: 5134995. DOI: 10.1056/NEJMoa1606221. View

18.

Anota A, Mariet A, Maingon P, Joly F, Bosset J, Guizard A . Cross-cultural adaptation and validation of the French version of the Expanded Prostate cancer Index Composite questionnaire for health-related quality of life in prostate cancer patients. Health Qual Life Outcomes. 2016; 14(1):168. PMC: 5139103. DOI: 10.1186/s12955-016-0571-y. View

19.

Chen R, Basak R, Meyer A, Kuo T, Carpenter W, Agans R . Association Between Choice of Radical Prostatectomy, External Beam Radiotherapy, Brachytherapy, or Active Surveillance and Patient-Reported Quality of Life Among Men With Localized Prostate Cancer. JAMA. 2017; 317(11):1141-1150. PMC: 6284802. DOI: 10.1001/jama.2017.1652. View

20.

Lam W, Tse M, Ng C, Chung E, Fielding R . Psychometric Assessment of the Chinese Version of the Abbreviated Expanded Prostate Cancer Index Composite (EPIC-26) and the Clinical Practice Version (EPIC-CP) in Chinese Men With Prostate Cancer. J Pain Symptom Manage. 2017; 53(6):1085-1090. DOI: 10.1016/j.jpainsymman.2017.02.010. View